Study guide
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics
Key Takeaways Explain This Topic AI
Normal global cerebral blood flow averages 50 mL/100g/min (~750 mL/min or 15% of cardiac output), with grey matter receiving ~80 mL/100g/min and white matter receiving ~20 mL/100g/min.
Arterial carbon dioxide tension ( P a CO 2 P_a\text{CO}_2 P a CO 2 ) is the most potent physiological regulator of cerebral blood flow, displaying a linear response between 20 and 80 mmHg (2.7–10.7 kPa) where flow shifts by 1–2 mL/100g/min (2–4%) per 1 mmHg change in P a CO 2 P_a\text{CO}_2 P a CO 2 .
Cerebral autoregulation maintains constant perfusion across mean arterial pressures of 50 to 150 mmHg; chronic arterial hypertension shifts this autoregulatory plateau rightward, increasing vulnerability to cerebral ischemia during acute hypotension.
The Monro-Kellie doctrine states the rigid cranium has fixed volume shared by brain parenchyma (80%), blood (10%), and cerebrospinal fluid (10%); cerebral perfusion pressure is defined as C P P = M A P − I C P CPP = MAP - ICP CPP = M A P − I CP (or CVP if higher), with a clinical target > 60–70 mmHg.
Cerebrospinal fluid is produced at ~0.35 mL/min (~500 mL/day) primarily by the choroid plexuses and reabsorbed across arachnoid villi into dural venous sinuses down a hydrostatic pressure gradient.
Last updated: October 2026
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics
Understanding neurophysiology is essential for neuroanaesthesia and neurocritical care. The brain represents only 2% of total body weight (~1400 g in an adult) yet consumes 20% of resting oxygen and 25% of systemic glucose. Because brain tissue lacks meaningful intracellular nutrient storage, neuronal viability depends on an uninterrupted, highly regulated cerebral microcirculation.
1. Quantitative Foundations of Cerebral Perfusion and Metabolism
Normal resting global cerebral blood flow (CBF) averages 50 mL/100g/min (approximate range: 45–55 mL/100g/min). In an adult with an average brain mass of 1400 g, total CBF is approximately 750 mL/min , representing 15% of resting cardiac output .
Perfusion is markedly heterogeneous throughout the brain:
Cortical grey matter: Receives approximately 80 mL/100g/min , reflecting high neuronal cell body density and intense synaptic activity.
Subcortical white matter: Receives approximately 20 mL/100g/min , reflecting the lower metabolic maintenance requirements of myelinated axonal tracts.
Cerebral Metabolic Rate for Oxygen ( C M R O 2 CMRO_2 CMR O 2 )
The brain consumes oxygen at a resting rate of 3.0 to 3.5 mL/100g/min (~45–50 mL/min total, or 20% of whole-body basal V O 2 VO_2 V O 2 ). Cellular energy consumption is divided into two primary components:
Functional (signaling) metabolism (~60% of C M R O 2 CMRO_2 CMR O 2 ): Generates and restores ionic gradients across neuronal membranes following action potentials and synaptic transmission (primarily mediated by Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump activity).
Basal (cellular integrity) metabolism (~40% of C M R O 2 CMRO_2 CMR O 2 ): Maintains basic cellular architecture, organelle function, membrane synthesis, and intracellular transport.
Flow-Metabolism Coupling
Under physiological conditions, regional CBF is tightly coupled to local metabolic demand (metabolic autoregulation). Activated cortical regions release vasoactive mediators into the perivascular extracellular fluid, inducing local arteriolar vasodilation. Key mediators include:
- Hydrogen ions ( H + H^+ H + ) and lactate from local glycolysis
- Extracellular potassium ions ( K + K^+ K + ) released during repetitive neuronal depolarization
- Adenosine released from ATP hydrolysis
- Nitric oxide (NO) synthesized by neuronal and endothelial nitric oxide synthase (nNOS/eNOS)
Prostanoids and epoxyeicosatrienoic acids (EETs) released via astrocyte end-feet contacting cerebral microvessels
2. Autoregulation of Cerebral Blood Flow
Cerebral autoregulation describes the intrinsic capacity of the cerebral vascular bed to maintain a constant blood flow despite fluctuations in perfusion pressure.
CBF = CPP CVR \text{CBF} = \frac{\text{CPP}}{\text{CVR}} CBF = CVR CPP
Where CPP \text{CPP} CPP is cerebral perfusion pressure and CVR \text{CVR} CVR is cerebrovascular resistance.
The Autoregulation Plateau
In normotensive adults, CBF remains constant across a mean arterial pressure (MAP) range of 50 to 150 mmHg (or a CPP range of roughly 50 to 150 mmHg):
Myogenic mechanism (Bayliss effect): Increased transmural vascular wall tension stretches arteriolar smooth muscle, triggering membrane depolarization, calcium influx via L-type voltage-gated channels, and arteriolar constriction, which elevates CVR.
Lower limit of autoregulation (MAP ~50 mmHg): Arterioles reach maximal vasodilation. Below 50 mmHg, CBF becomes passively pressure-dependent. Perfusion falls linearly, causing hypoperfusion, tissue hypoxia, cellular energy failure, and ischemia.
Upper limit of autoregulation (MAP ~150 mmHg): Arteriolar smooth muscle cannot resist intraluminal hydrostatic pressure. Vasoconstriction fails, resulting in "forced vasodilation" (autoregulatory breakthrough). High pressure transmits directly into fragile capillaries, causing blood-brain barrier disruption, vasogenic cerebral edema, microhemorrhages, and hypertensive encephalopathy. CBF (mL/100g/min)
- ^
- 100 | Breakthrough Hyperperfusion
- | /---------
- 50 | /====================/
- | / (Autoregulatory Plateau)
- | / MAP 50 - 150 mmHg
- | /
- | / Ischemic
- 0 +----+-----+-----+-----+-----+-----+-----> MAP (mmHg)
- 0 25 50 75 100 125 150 175
- Pathophysiological Shifts in Autoregulation
Chronic arterial hypertension: Structural vascular remodeling (smooth muscle hypertrophy and arteriolar hyalinosis) shifts the entire autoregulation curve to the right (e.g., limits shift to 80–180 mmHg MAP). While this protects the microvasculature from acute pressure spikes, the lower limit of autoregulation is elevated. Acute reductions of blood pressure into the "normal" range (e.g., MAP 65 mmHg) can precipitate severe cerebral ischemia.
Acute brain pathology: Severe traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), ischemic stroke, and central nervous system infections frequently abolish autoregulation entirely ("pressure-passive" circulation). In this state, any reduction in MAP directly lowers CBF, while any increase in MAP elevates ICP.
3. Chemical, Physical, and Pharmacological Determinants of CBF
Determinant Physiological Mechanism Magnitude of Effect Clinical Key Note
P a CO 2 P_a\text{CO}_2 P a CO 2 Rapid diffusion across BBB alters perivascular extracellular [ H + ] [H^+] [ H + ] 1–2 mL/100g/min per 1 mmHg change (2–4% per mmHg) Linear between 20–80 mmHg (2.7–10.7 kPa); CSF buffering resets tone within 24–48 hours
P a O 2 P_a\text{O}_2 P a O 2 Tissue hypoxia triggers local adenosine and NO release Minimal effect when P a O 2 > 60 mmHg P_a\text{O}_2 > 60\text{ mmHg} P a O 2 > 60 mmHg ; marked exponential CBF rise below 50 mmHg Hyperoxia causes modest vasoconstriction (~10–15% CBF reduction at 100% O 2 O_2 O 2 )
Temperature Modulates enzymatic activity and baseline metabolic rate ( Q 10 Q_{10} Q 10 ) C M R O 2 CMRO_2 CMR O 2 and CBF change ~7% per 1°C alteration Hypothermia to 18–20°C produces isoelectric EEG; hyperthermia accelerates neuronal death
Volatiles Direct vascular smooth muscle relaxation vs metabolic suppression Uncouples flow from metabolism; vasodilation dominates at >1.0 MAC Blunted by mild hyperventilation ( P a CO 2 P_a\text{CO}_2 P a CO 2 30–35 mmHg) and co-administration of IV agents
IV Agents Suppress neuronal electrical activity; preserve coupling Parallel drop in C M R O 2 CMRO_2 CMR O 2 and CBF (except ketamine) Propofol and thiopental lower ICP; ketamine increases C M R O 2 CMRO_2 CMR O 2 and CBF
Arterial Carbon Dioxide Tension ( P a CO 2 P_a\text{CO}_2 P a CO 2 )
Carbon dioxide is the most potent physiological chemical regulator of cerebral vasomotor tone. Between 20 and 80 mmHg (2.7 to 10.7 kPa) , the relationship between P a CO 2 P_a\text{CO}_2 P a CO 2 and CBF is nearly linear:
For every 1 mmHg change in P a CO 2 P_a\text{CO}_2 P a CO 2 , CBF changes by 1 to 2 mL/100g/min (approx. 2–4% change in flow).
Mechanism: Molecular C O 2 CO_2 C O 2 is highly lipophilic and diffuses rapidly across the blood-brain barrier. In the perivascular extracellular fluid, C O 2 + H 2 O ⇌ H 2 C O 3 ⇌ H + + HCO 3 − CO_2 + H_2O \rightleftharpoons H_2CO_3 \rightleftharpoons H^+ + \text{HCO}_3^- C O 2 + H 2 O ⇌ H 2 C O 3 ⇌ H + + HCO 3 − . Elevated [ H + ] [H^+] [ H + ] relaxes vascular smooth muscle via potassium channel activation ( K ATP K_{\text{ATP}} K ATP and K Ca K_{\text{Ca}} K Ca ). Conversely, systemic arterial [ H + ] [H^+] [ H + ] cannot cross the intact BBB and has no direct immediate effect on CBF.
Temporal limitation: Hyperventilation lowers P a CO 2 P_a\text{CO}_2 P a CO 2 and rapidly constricts cerebral vessels, lowering ICP within minutes. However, active transport of bicarbonate out of the CSF and choroid plexus buffering restores perivascular pH to normal within 24 to 48 hours . Therefore, therapeutic hyperventilation is a temporary bridge, and abrupt cessation causes rebound vasodilation and ICP spikes.
Temperature and the Q 10 Q_{10} Q 10 Effect
Cerebral metabolism follows the temperature coefficient ( Q 10 Q_{10} Q 10 ), which for the human brain is approximately 2.0 to 2.5 . C M R O 2 CMRO_2 CMR O 2 decreases by approximately 7% for every 1°C decrease in brain temperature :
Deep hypothermia (18–20°C): Induces electroencephalographic (EEG) silence. Because functional electrical metabolism (~60%) is extinguished and basal cellular metabolism is halved, brain tolerance to complete circulatory arrest increases from 5 minutes at 37°C to over 30–45 minutes at 18°C.
Hyperthermia: Fever markedly increases C M R O 2 CMRO_2 CMR O 2 and CBF, aggravates secondary ischemic injury, and promotes intracranial hypertension. Maintaining strict normothermia (36.0–37.0°C) is mandatory in neurocritical care.
Anaesthetic Pharmacology on CBF and C M R O 2 CMRO_2 CMR O 2
Volatile Inhalational Anaesthetics (isoflurane, sevoflurane, desflurane): Possess dose-dependent dual actions. They suppress neuronal metabolic activity (reducing C M R O 2 CMRO_2 CMR O 2 ), but exert direct smooth muscle relaxant effects on cerebral arterioles. Below 1.0 MAC, metabolic suppression balances vasodilation; above 1.0 MAC, direct vasodilation dominates, causing increased CBF, cerebral blood volume, and ICP.
Nitrous Oxide ( N 2 O N_2O N 2 O ): Produces cerebral vasodilation and increases both C M R O 2 CMRO_2 CMR O 2 and CBF, particularly when combined with volatile agents.
Intravenous Induction Agents (propofol, thiopental, etomidate): Maintain intact flow-metabolism coupling. They cause parallel, dose-dependent reductions in both C M R O 2 CMRO_2 CMR O 2 and CBF (up to a ceiling of 50–55% suppression when burst suppression is achieved on EEG), reducing cerebral blood volume and ICP.
Ketamine: Unique exception among IV agents. As a non-competitive NMDA receptor antagonist, ketamine stimulates limbic structures, increases C M R O 2 CMRO_2 CMR O 2 , and causes profound cerebral vasodilation, increasing CBF by up to 60%. Although its ICP-elevating effects can be partially blunted by controlled normocapnic ventilation and co-administration of GABAergic agents, ketamine is traditionally avoided in acute neurotrauma with compromised intracranial compliance.
- 4. Intracranial Pressure Dynamics and the Monro-Kellie Doctrine
- The Monro-Kellie Hypothesis
The cranium is a rigid, non-distensible vault with a fixed internal volume. In a healthy adult, this space is occupied by three distinct physiological compartments:
V intracranial = V brain + V CSF + V blood = Constant V_{\text{intracranial}} = V_{\text{brain}} + V_{\text{CSF}} + V_{\text{blood}} = \text{Constant} V intracranial = V brain + V CSF + V blood = Constant
- Brain parenchyma: ~80% (~1400 mL; intracellular and extracellular fluid, glia, neurons)
- Cerebrospinal fluid (CSF): ~10% (~150 mL)
Intracranial blood: ~10% (~150 mL; ~70–80% resides in low-pressure venous sinuses and capillarovenous beds, ~20–30% in arterial vessels)
Because total intracranial volume is constant, an abnormal volume addition (e.g., hematoma, tumor, cerebral edema) must be offset by an equal reduction in one or both of the physiological fluid compartments. This is the spatial compensation phase :
Translocation of CSF out of the cranial vault into the compliant lumbosacral spinal subarachnoid space.
Acceleration of CSF absorption through arachnoid villi into the superior sagittal sinus.
Compression and displacement of low-pressure cerebral veins and dural venous blood into the systemic circulation. ICP (mmHg)
- ^
- 60 | / (Decompensated)
- | / High Elastance
- 40 | /
- | /
- 20 | ___________/
- | / (Knee of Curve: Spatial Exhaustion)
- 0 +------------------------+------------------------------------> Intracranial Volume
- 0 Compensated Phase (High Compliance)
- Intracranial Compliance and Elastance
Compliance ( C = Δ V Δ P C = \frac{\Delta V}{\Delta P} C = Δ P Δ V ): The change in volume per unit change in pressure. During early mass expansion, compliance is high, so ICP remains within normal limits ( 5 to 15 mmHg ).
Elastance ( E = Δ P Δ V E = \frac{\Delta P}{\Delta V} E = Δ V Δ P ): The inverse of compliance. Once spatial compensatory mechanisms are exhausted ("the knee of the curve"), compliance plummets and elastance rises steeply. At this point, minute volume additions (e.g., 2–5 mL from cough-induced venous engorgement or hypercapnic vasodilation) provoke massive spikes in ICP.
Pathological threshold: Sustained intracranial pressure > 20 to 22 mmHg requires aggressive intervention to prevent secondary ischemia and cerebral herniation.
Cerebral Perfusion Pressure (CPP)
Cerebral perfusion pressure drives blood across the cerebral vascular bed:
C P P = M A P − I C P ( or C V P , whichever is higher ) CPP = MAP - ICP \quad (\text{or } CVP, \text{ whichever is higher}) CPP = M A P − I CP ( or C V P , whichever is higher )
Under normal conditions, ICP (5–15 mmHg) exceeds central venous pressure (CVP). However, if CVP is pathologically elevated (e.g., tension pneumothorax, excessive PEEP, tricuspid regurgitation), CVP replaces ICP as the effective backpressure (Starling resistor mechanism).
Clinical targets: In traumatic brain injury and neurocritical care, the internationally recommended target CPP is 60 to 70 mmHg .
Risks of extremes: A CPP < 60 mmHg risks secondary ischemic insult. Conversely, aggressively driving CPP > 70–80 mmHg with high-dose vasopressors increases hydrostatic capillary filtration, aggravating vasogenic brain edema and increasing the incidence of acute respiratory distress syndrome (ARDS).
Brain Herniation Syndromes
When compartmental pressure gradients develop across rigid intracranial dural folds, brain tissue shifts:
Uncal (transtentorial) herniation: Medial temporal lobe (uncus) herniates downward through the tentorial notch. Compresses the ipsilateral oculomotor nerve (CN III) causing an ipsilateral fixed, dilated pupil, and compresses the midbrain cerebral peduncle causing contralateral hemiparesis (Kernohan notch phenomenon can cause paradoxical ipsilateral hemiparesis).
Subfalcine (cingulate) herniation: Cingulate gyrus shifts under the falx cerebri, compressing the anterior cerebral artery (ACA) and causing contralateral lower extremity weakness.
Central tentorial herniation: Downward displacement of bilateral cerebral hemispheres and basal ganglia compressing the diencephalon and brainstem, causing decorticate posturing progressing to decerebrate rigidity.
Cerebellar tonsillar herniation ("coning"): Cerebellar tonsils are forced downward through the foramen magnum, compressing the medulla oblongata, leading to respiratory arrest, sudden Cushing triad (hypertension, bradycardia, irregular respiration), and death.
- 5. Cerebrospinal Fluid (CSF) Physiology and Blood-Brain Barrier (BBB)
- CSF Formation and Circulation
Volume and Production: Total adult CSF volume is approximately 150 mL (~25–30 mL in the cerebral ventricles, remainder in the subarachnoid space). CSF is produced at 0.35 mL/min (~500 mL/day) , meaning the total CSF pool turns over 3 to 4 times per day .
Sites of production: Approximately 70–80% is secreted actively by the choroid plexuses situated within the lateral, third, and fourth ventricles; the remaining 20–30% originates as interstitial fluid filtration across ependymal surfaces.
Cellular mechanism: Polarized choroid epithelial cells use basolateral Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase and carbonic anhydrase to transport sodium and bicarbonate into the ventricles, with water following down the resulting osmotic gradient through aquaporin-1 channels. Production is an active metabolic process that remains constant over normal physiological ranges of ICP, declining only when CPP approaches zero.
Circulation pathway: Lateral Ventricles → Foramina of Monro Third Ventricle → Aqueduct of Sylvius Fourth Ventricle \text{Lateral Ventricles} \xrightarrow{\text{Foramina of Monro}} \text{Third Ventricle} \xrightarrow{\text{Aqueduct of Sylvius}} \text{Fourth Ventricle} Lateral Ventricles Foramina of Monro Third Ventricle Aqueduct of Sylvius Fourth Ventricle → Foramina of Luschka (lateral) & Magendie (midline) Cisterna Magna & Subarachnoid Space → Arachnoid Granulations \xrightarrow{\text{Foramina of Luschka (lateral) \& Magendie (midline)}} \text{Cisterna Magna \& Subarachnoid Space} \xrightarrow{} \text{Arachnoid Granulations} Foramina of Luschka (lateral) & Magendie (midline) Cisterna Magna & Subarachnoid Space Arachnoid Granulations
Reabsorption: CSF is reabsorbed into the superior sagittal and dural venous sinuses via arachnoid villi and granulations . Reabsorption is a passive, bulk-flow process governed by the hydrostatic pressure gradient between CSF and dural sinus blood (normal gradient ~5–7 cmH 2 O \text{cmH}_2\text{O} cmH 2 O ). Arachnoid villi act as one-way micro-valves; when ICP exceeds dural venous pressure, valves open. If dural pressure exceeds ICP, the villi collapse, preventing venous reflux.
Blood-Brain Barrier (BBB) Structure
The BBB isolates the cerebral microenvironment from systemic circulating neurotoxins, neurotransmitters, and electrolyte fluctuations:
Continuous, non-fenestrated capillary endothelial cells: Sealed by complex, high-electrical-resistance intercellular tight junctions (claudins, occludins, junctional adhesion molecules, and zonula occludens ZO-1).
Basement membrane: Continuous basal lamina enclosing pericytes.
Astrocyte end-feet: Ensheath 99% of the capillary surface, inducing and maintaining tight junction integrity.
Permeability characteristics: Lipophilic molecules (volatile anaesthetics, opioids, benzodiazepines, O 2 , C O 2 O_2, CO_2 O 2 , C O 2 ) diffuse freely across the lipid membranes. Water-soluble, charged, or polar compounds (ions, mannitol, proteins) cannot pass passively and require specialized carrier proteins or receptor-mediated transport. The reflection coefficient ( σ \sigma σ ) for sodium, chloride, and mannitol across an intact BBB is close to 1.0 (impermeable).
Osmotherapy: Mannitol vs Hypertonic Saline
When the BBB is intact, administering hypertonic solutions expands intravascular osmolality, establishing a trans-endothelial osmotic pressure gradient that draws free water from the intracellular and interstitial compartments of normal brain tissue into the cerebral circulation, shrinking brain volume and lowering ICP within minutes.
Feature Mannitol (20% solution) Hypertonic Saline (3% to 7.5% NaCl)
Dose & Administration 0.25–1.0 g/kg IV over 15–20 minutes 2–3 mL/kg of 3% NaCl (or 30 mL of 23.4% NaCl via a central line)
Mechanism of Action (1) Immediate rheological effect (expands plasma volume, hemodilutes, reduces blood viscosity, reflexively constricts arterioles via autoregulation); (2) Delayed osmotic dehydration of intact brain parenchyma (1) Rapid osmotic brain dehydration; (2) Intravascular volume expansion without diuresis; (3) Restores endothelial resting membrane potential; (4) Anti-inflammatory microvascular effects
Onset & Duration Onset: 10–15 min; Peak: 30–45 min; Duration: 2–6 hours Onset: 5–10 min; Duration: 2–6 hours
Elimination & Renal Effect Filtered by glomerulus without reabsorption; produces profound osmotic diuresis Excreted by kidneys via normal natriuresis; preserves intravascular volume
Adverse Effects & Traps Hypovolemia, hypotension, hypokalemia, acute tubular injury (if serum osmolality > 320 mOsm/kg > 320\text{ mOsm/kg} > 320 mOsm/kg ); rebound ICP elevation if it leaks across disrupted BBB Hypernatremia ( > 155 mmol/L >155\text{ mmol/L} > 155 mmol/L ), hyperchloremic metabolic acidosis, fluid overload/pulmonary edema; pontine myelinolysis if chronic hyponatremia is overcorrected